Pliva
A Croatian pharmaceutical company focused primarily on generic medicines and pharmaceutical ingredients.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Pliva is a Croatian pharmaceutical company headquartered in Zagreb and operating as part of Teva Pharmaceutical Industries. Its principal business is the manufacture and sale of generic medicines, together with pharmaceutical ingredients and related products. The company is one of the best-known pharmaceutical businesses to emerge from Croatia and has historically served both its domestic market and international customers. The enterprise traces its origins to the pharmaceutical factory Kaštel d.d., established in Karlovac in 1921 as a joint venture involving Gustav Janeček's wholesale drug business Isis, the Budapest-based pharmaceutical company Chinoin, and associated investors. Production was moved to Zagreb in 1927. In 1941, the company adopted the name PLIVA, derived from the Croatian state institute responsible for producing medicines and vaccines. This institutional history gave the brand a prominent place in the development of the Croatian pharmaceutical sector. Pliva's most important scientific achievement was the discovery of azithromycin in 1980. The research project was led by Dr. Slobodan Đokić, with researchers Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski, and Zrinka Tamburašev among the team. Azithromycin subsequently became a major antibiotic product worldwide, marketed under the Sumamed brand by Pliva and under other names by licensees and generic manufacturers. The discovery remains central to Pliva's corporate identity and to Croatia's international pharmaceutical reputation. During the 2000s, Pliva expanded through acquisitions, regulatory approvals, and a stronger focus on generic medicines. It acquired Sidmak in 2002 and obtained approvals for products including trospium chloride, generic erythropoietin, generic azithromycin, citalopram, and ondansetron. Barr Pharmaceuticals acquired Pliva in 2006. Barr was subsequently acquired by Teva Pharmaceutical Industries in 2008, making Pliva part of Teva's international generic-drug and active-pharmaceutical-ingredient network. Under Teva ownership, Pliva continues to operate as a Croatian pharmaceutical business with manufacturing, development, and commercial activities connected to Teva's broader portfolio. Its typical products include prescription generics, selected over-the-counter medicines, antibiotics, cardiovascular and central-nervous-system medicines, and pharmaceutical active ingredients. Pliva is also described as one of the world's large producers of generic mixed amphetamine salts, commonly associated with generic Adderall, although the availability and commercial status of individual products vary by market and regulatory authorization. Pliva's positioning combines Croatian pharmaceutical heritage, scientific discovery, manufacturing capability, and access to Teva's global generic-medicines infrastructure. The brand is best understood not as an independent publicly traded company today, but as a national pharmaceutical brand operating within a multinational group.
History
Pliva's roots lie in the formation of Kaštel d.d. in 1921. The company was established in Karlovac as a joint venture involving Gustav Janeček's wholesale pharmaceutical business Isis, the Budapest-based company Chinoin, and other associated interests. Janeček became the first president of the board. Production later moved to Zagreb in 1927, establishing the location that would become the company's long-term headquarters and the center of its Croatian industrial identity. The name Pliva was adopted in 1941. It was formed as an acronym connected with the State Institute for Production of Medicines and Vaccines. Over subsequent decades, the company developed into a major Yugoslav and later Croatian pharmaceutical manufacturer. Its activities included the production and sale of medicines as well as pharmaceutical substances used in drug manufacturing. The company's defining scientific milestone occurred in 1980, when a Pliva research team discovered azithromycin. The work was led by Dr. Slobodan Đokić, with Gabrijela Kobrehel, Gorjana Radobolja-Lazarevski, and Zrinka Tamburašev identified among the researchers. Azithromycin became a significant macrolide antibiotic and was commercialized by Pliva as Sumamed. Licensing and subsequent market participation by other pharmaceutical companies helped make the molecule internationally important. The discovery remains Pliva's most widely recognized contribution to pharmaceutical science. In the early 2000s, Pliva pursued international growth through acquisitions and regulatory expansion. It acquired Sidmak in June 2002. The company also sought approvals for generic products in the United States and Croatia, including trospium chloride, erythropoietin, azithromycin, citalopram, and ondansetron. These approvals reflected a strategic emphasis on regulated generic medicines and on expanding the geographic reach of its portfolio. Barr Pharmaceuticals acquired Pliva in October 2006. The transaction placed Pliva within a larger international generic-drug group. In December 2008, Teva Pharmaceutical Industries acquired Barr. Pliva consequently became part of Teva's global business and was connected to Teva's generic pharmaceuticals and active-pharmaceutical-ingredient operations. Today, Pliva operates as a Teva subsidiary rather than as an independent pharmaceutical group. Its brand continues to represent Croatian pharmaceutical manufacturing and research while its products, production capabilities, and commercial activities are integrated with a multinational generic-medicines platform. The company's historical identity is anchored in three themes: the development of Zagreb as a pharmaceutical production center, the discovery of azithromycin, and the transition from a nationally significant manufacturer to a subsidiary within the global Teva organization.
- 2008
Teva acquired Barr Pharmaceuticals
[1]Teva's acquisition of Barr Pharmaceuticals brought Pliva into Teva's global generic-drug and active-ingredient operations.
- 2006
Barr Pharmaceuticals acquired Pliva
[1]Barr Pharmaceuticals acquired Pliva in October, beginning the company's transition into a larger international pharmaceutical group.
- 2005
Generic erythropoietin approved in Croatia
[1]Pliva received Croatian approval to sell a generic version of erythropoietin.
- 2005
Three generic medicines approved in the United States
[1]U.S. regulators approved Pliva's generic versions of azithromycin, citalopram, and ondansetron.
- 2004
U.S. approval for trospium chloride
[1]The U.S. Food and Drug Administration approved Pliva's sale of trospium chloride.
- 2002
Sidmak acquired
[1]Pliva acquired Sidmak in June 2002 for a reported $152.9 million.
- 1980
Azithromycin discovered
[1]A Pliva research team led by Slobodan Đokić discovered azithromycin, later commercialized by Pliva as Sumamed.
- 1941
The Pliva name was adopted
[1]The company was renamed PLIVA, an acronym associated with the state institute for producing medicines and vaccines.
- 1927
Production moved to Zagreb
[1]Kaštel moved its production from Karlovac to Zagreb, which later became Pliva's headquarters and principal Croatian base.
- 1921
Kaštel d.d. founded
[1]Gustav Janeček co-founded the pharmaceutical factory Kaštel d.d. in Karlovac with Isis and Chinoin and became its first board president.
Products and positioning
A Croatian pharmaceutical heritage brand specializing in generic medicines, pharmaceutical ingredients, and internationally distributed products within Teva's global platform.
Antibiotic
Azithromycin
Azithromycin is Pliva's signature scientific contribution. Discovered by a Pliva research team in 1980, it is a macrolide antibiotic used against a range of bacterial infections. Pliva commercialized the medicine under the Sumamed name, while the active ingredient has also been distributed through licensing and generic products in many markets.
Prescription antibiotic brand
Sumamed
Sumamed is Pliva's branded presentation of azithromycin and one of the products most closely associated with the company's international identity. It represents the commercial outcome of Pliva's 1980 discovery and has been used as an antibiotic product in markets where the brand is authorized.
Central nervous system generic
Generic mixed amphetamine salts
Pliva is identified as one of the world's large producers of generic mixed amphetamine salts, the active pharmaceutical combination commonly associated with generic Adderall. Distribution, authorization, and formulation availability depend on national regulatory approvals and commercial arrangements.
Generic prescription medicine · 2004
Trospium chloride
Trospium chloride is a prescription medicine for which Pliva received U.S. Food and Drug Administration approval in 2004. It illustrates the company's strategy of developing and registering generic and specialty pharmaceutical products in regulated international markets.
Biopharmaceutical generic · 2005
Generic erythropoietin
Pliva received approval in Croatia in 2005 to sell a generic version of erythropoietin. The approval expanded the company's domestic generic portfolio into a biologically derived therapeutic category.
Central nervous system generic · 2005
Citalopram
Pliva received U.S. approval in 2005 for a generic version of citalopram, an antidepressant. The approval formed part of a group of U.S. regulatory milestones that also covered generic azithromycin and ondansetron.
Supportive-care generic · 2005
Ondansetron
Ondansetron was among the medicines for which Pliva received U.S. generic approval in 2005. The medicine is used to help prevent nausea and vomiting, particularly in clinical-care settings, subject to local authorization and labeling.
Brand decisions
2008
Integration into TevaM&ABackground
Teva Pharmaceutical Industries acquired Barr Pharmaceuticals, Pliva's parent company.
Action taken
Teva acquired Barr on December 23, 2008, bringing Pliva into Teva's generic-pharmaceutical and active-ingredient network.
Aftermath
Pliva continued as a Croatian pharmaceutical subsidiary within Teva rather than as an independent pharmaceutical group.
2006
Barr Pharmaceuticals acquisitionM&ABackground
Pliva's generic-drug business had become an attractive acquisition target as international pharmaceutical groups expanded their generic portfolios.
Action taken
Barr Pharmaceuticals acquired Pliva in October 2006.
Aftermath
Pliva became part of Barr's international pharmaceutical organization until Barr was acquired by Teva in 2008.
2002
Acquisition of SidmakM&ABackground
Pliva pursued expansion through the acquisition of Sidmak during a period when it was broadening its international pharmaceutical activities.
Action taken
Pliva acquired Sidmak in June 2002.
Aftermath
The acquisition formed part of Pliva's early-2000s expansion, although the available reference material does not provide detailed operational results.
Acquisition price. $152.9 million (June 2002)
Recent events
- 2008
Pliva became part of Teva's pharmaceutical network[1]
M&A
Teva Pharmaceutical Industries acquired Barr Pharmaceuticals in December 2008, after which Pliva became part of Teva's operations, including the Teva Active Pharmaceutical Ingredients network.
- 2006
Barr Pharmaceuticals acquired Pliva[1]
M&A
Barr Pharmaceuticals acquired Pliva in October 2006, transferring the Croatian company into Barr's pharmaceutical group.
- 2005
Pliva received Croatian approval for generic erythropoietin[1]
Regulation · Product launch
Pliva received approval to sell a generic version of erythropoietin in Croatia.
- 2005
Pliva received U.S. approvals for three generic medicines[1]
Regulation · Product launch
The company received U.S. approval for generic versions of azithromycin, citalopram, and ondansetron.
- 2004
Pliva received U.S. approval for trospium chloride[1]
Regulation
The company received approval from the U.S. Food and Drug Administration to sell trospium chloride.
- 2002
Pliva acquired Sidmak[1]
M&A
Pliva acquired Sidmak in June 2002 as part of its expansion activity.
- 2002
Pliva chief financial officer resigned[1]
Leadership change
Zeljko Peric, Pliva's chief financial officer, resigned in June 2002.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/pliva · Editorial policy · How profiles are compiled